SHUKRA PHARMACEUTICALS
|
SHUKRA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.22 | 16.94 | 11.26 | 4.79 | 1.20 |
| CEPS(Rs) | 0.29 | 0.47 | 0.40 | 0.08 | 0.06 |
| DPS(Rs) | 0.01 | 1.00 | 0.50 | 0.50 | - |
| Book NAV/Share(Rs) | 1.44 | 52.67 | 64.63 | 104.43 | 99.63 |
| Tax Rate(%) | 28.20 | 6.77 | 0.79 | 26.26 | -92.33 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 39.06 | 26.02 | 9.12 | 14.09 | 12.90 |
| EBIT Margin(%) | 42.75 | 27.05 | 8.03 | 6.37 | 1.17 |
| Pre Tax Margin(%) | 40.93 | 26.66 | 7.55 | 4.97 | 0.87 |
| PAT Margin (%) | 29.38 | 24.86 | 7.49 | 3.66 | 1.68 |
| Cash Profit Margin (%) | 38.60 | 27.61 | 10.61 | 11.78 | 14.84 |
| Performance Ratios | |||||
| ROA(%) | 11.63 | 24.26 | 8.01 | 2.12 | 0.54 |
| ROE(%) | 15.90 | 44.70 | 21.16 | 4.70 | 1.21 |
| ROCE(%) | 21.80 | 44.24 | 18.85 | 5.79 | 0.54 |
| Asset Turnover(x) | 0.40 | 0.98 | 1.07 | 0.58 | 0.32 |
| Sales/Fixed Asset(x) | 0.77 | 1.85 | 1.58 | 0.60 | 0.34 |
| Working Capital/Sales(x) | 0.68 | 1.77 | 5.57 | 5.86 | 1.24 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.29 | 0.54 | 0.63 | 1.67 | 2.91 |
| Receivable days | 186.38 | 133.86 | 116.60 | 152.77 | 288.50 |
| Inventory Days | 68.70 | 13.39 | 22.06 | 50.20 | 50.01 |
| Payable days | 369.82 | 167.55 | 170.00 | 245.53 | 761.94 |
| Valuation Parameters | |||||
| PER(x) | 99.91 | 0.48 | 1.04 | 2.62 | 7.71 |
| PCE(x) | 76.05 | 17.36 | 2.94 | 3.92 | 4.19 |
| Price/Book(x) | 15.23 | 6.20 | 0.73 | 0.58 | 0.45 |
| Yield(%) | 0.05 | 0.31 | 1.07 | 0.83 | - |
| EV/Net Sales(x) | 29.12 | 4.70 | 0.33 | 0.61 | 1.45 |
| EV/Core EBITDA(x) | 56.02 | 15.78 | 2.97 | 4.23 | 9.02 |
| EV/EBIT(x) | 68.11 | 17.38 | 4.12 | 9.61 | 123.83 |
| EV/CE(x) | 14.16 | 5.77 | 0.64 | 0.64 | 0.64 |
| M Cap / Sales | 29.36 | 4.79 | 0.31 | 0.46 | 0.62 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -56.30 | 26.75 | 187.19 | 82.97 | -5.49 |
| Core EBITDA Growth(%) | -23.77 | 238.70 | 121.12 | 64.81 | 16.13 |
| EBIT Growth(%) | -30.92 | 327.07 | 261.99 | 895.12 | -24.17 |
| PAT Growth(%) | -48.35 | 320.68 | 486.99 | 299.10 | 428.31 |
| EPS Growth(%) | -98.71 | 50.47 | 134.80 | 299.10 | 428.30 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.05 | 0.20 | 0.21 | 0.63 |
| Current Ratio(x) | 3.79 | 3.97 | 1.25 | 1.28 | 2.28 |
| Quick Ratio(x) | 3.21 | 3.81 | 1.17 | 0.96 | 2.04 |
| Interest Cover(x) | 23.42 | 70.77 | 16.82 | 4.55 | 3.94 |
| Total Debt/Mcap(x) | - | 0.01 | 0.10 | 0.36 | 1.40 |
Compare Financial Ratios of peers of SHUKRA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SHUKRA PHARMACEUTICALS | ₹2,343.2 Cr | 13.1% | -5.1% | 171.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹400,497.0 Cr | -3.5% | -6.4% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹165,492.0 Cr | -5.8% | -1.6% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹136,013.0 Cr | 1.4% | 7% | 23.7% | Stock Analytics | |
| CIPLA | ₹112,922.0 Cr | -4.7% | -6.8% | -0.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,115.0 Cr | -2.8% | -8.1% | -11.1% | Stock Analytics | |
SHUKRA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SHUKRA PHARMACEUTICALS | 13.1% |
-5.1% |
171.6% |
| SENSEX | -0.7% |
-1.9% |
8% |
You may also like the below Video Courses
